See more : Ozon Holdings PLC (OZON) Income Statement Analysis – Financial Results
Complete financial analysis of Calidi Biotherapeutics, Inc. (CLDI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calidi Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KUKA Aktiengesellschaft (KU2.SW) Income Statement Analysis – Financial Results
- Vector Group Ltd. (VGR) Income Statement Analysis – Financial Results
- TechGen Metals Ltd (TG1.AX) Income Statement Analysis – Financial Results
- China High Speed Transmission Equipment Group Co., Ltd. (CHSTF) Income Statement Analysis – Financial Results
- Aryaman Financial Services Limited (ARYAMAN.BO) Income Statement Analysis – Financial Results
Calidi Biotherapeutics, Inc. (CLDI)
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 45.00K | 449.00K | 0.00 |
| Cost of Revenue | 1.26M | 274.00K | 94.00K | 0.00 |
| Gross Profit | -1.26M | -229.00K | 355.00K | 0.00 |
| Gross Profit Ratio | 0.00% | -508.89% | 79.06% | 0.00% |
| Research & Development | 13.01M | 7.26M | 4.67M | 3.18M |
| General & Administrative | 15.98M | 15.90M | 6.16M | 3.59M |
| Selling & Marketing | 0.00 | -260.00K | -4.38M | 0.00 |
| SG&A | 15.98M | 15.64M | 1.78M | 3.59M |
| Other Expenses | 0.00 | -5.00K | 9.00K | 4.00K |
| Operating Expenses | 28.99M | 22.90M | 1.78M | 6.77M |
| Cost & Expenses | 28.99M | 23.17M | 1.78M | 6.77M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.07M | 158.00K | 614.00K | 163.00K |
| Depreciation & Amortization | 1.26M | 260.00K | 153.00K | 117.00K |
| EBITDA | -27.58M | -25.00M | -9.45M | -6.65M |
| EBITDA Ratio | 0.00% | -50,817.78% | -396.82% | 0.00% |
| Operating Income | -28.99M | -23.13M | -1.78M | -6.77M |
| Operating Income Ratio | 0.00% | -51,395.56% | -396.82% | 0.00% |
| Total Other Income/Expenses | -208.00K | -2.29M | -440.00K | -1.16M |
| Income Before Tax | -29.20M | -25.42M | 3.39M | -7.93M |
| Income Before Tax Ratio | 0.00% | -56,480.00% | 754.29% | 0.00% |
| Income Tax Expense | 16.00K | 11.00K | 11.00K | 4.00K |
| Net Income | -29.22M | -25.43M | 3.39M | -7.94M |
| Net Income Ratio | 0.00% | -56,504.44% | 754.29% | 0.00% |
| EPS | -1.73 | -29.90 | 1.18 | -0.22 |
| EPS Diluted | -17.30 | -29.90 | 1.18 | -0.22 |
| Weighted Avg Shares Out | 16.89M | 850.50K | 2.88M | 35.91M |
| Weighted Avg Shares Out (Dil) | 1.69M | 850.50K | 2.88M | 35.91M |
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares...
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has priced its public offering of 4,437,869 shares...
Calidi Biotherapeutics Announces Proposed Public Offering
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its...
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the third quarter ended September...
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this...
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases, offering a potential transformative solution with wide-ranging applications SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE)...
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement...
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that the staff of NYSE Regulation has determined to commence proceedings...
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Gorilla Technology Group Inc. (Nasdaq:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV,...
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants — ticker symbol CLDI WS — of Calidi Biotherapeutics, Inc. (the “Company”), each...
Source: https://incomestatements.info
Category: Stock Reports